

CURRICULUM VITAE

KATHERINE (KATYA) B. O'LEARY

2120 Lynngate Drive
Birmingham, AL 35216
Phone: (205) 823-0766

PROFESSIONAL EXPERIENCE:

August 1990 to Present	Research Manager Birmingham Research Group, Inc.
February 1989 - August 1990	Clinical Research Associate Birmingham Research Group, Inc.
1981 - 1985	Elementary Teacher Baltimore City Board of Education Baltimore, MD

ADDITIONAL TRAINING & CERTIFICATION:

July 1992	Certified Clinical Research Coordinator Associates of Clinical Pharmacology
September 1991	Associates of Clinical Pharmacology Advanced Clinical Research Coordinator Symposium Boston, Massachusetts
November 1989	SCID-UP Training Course Conducted by Dr. Michael First
May 1982	Introductory Computer Course Loyolla College, Baltimore, MD

APPOINTMENTS:

Birmingham Research Group, Inc.
Board of Directors

EDUCATION:

1977 - 1981	Goucher College, Towson, MD Major: Education, BA. Graduated with honors in major and general studies. Awarded the Beulah Tatum Education Award
-------------	--

PERSONAL DATA:

DOB:	April 17, 1959
Citizenship:	United States
Marital Status:	Married
Children:	Two

RESEARCH INTEREST AND EXPERIENCE:

Anxiety, Panic & Phobic Disorders
 Chronic Pain, Migraine, Impotence
 Depression, Bipolar Disorder
 Schizophrenia, Post-Traumatic
 Stress Disorder, Alzheimer's Disease

CLINICAL TRIALS:

- 1989 Tramadol Hydrochloride: Safety and Efficacy Compared to Acetaminophen with Codeine Phosphate in Elderly Patients with Chronic Pain.
 Sponsor: McNeil Pharmaceuticals
- 1989 A Multicenter Study Comparing Xanax SR and Xanax SR Placebo Tablets in the Treatment of Panic Disorder. Protocol # 4452.
 Sponsor: The Upjohn Company
- 1989 A Double-Blind Evaluation of the Safety and Efficacy of ZK 112-119, Alprazolam and Placebo in Outpatients with Generalized Anxiety Disorder. Protocol # B202
 Sponsor: Sandoz Pharmaceuticals Corp.
- 1989 A Double-Blind Evaluation of the Safety and Efficacy of ZK 112-119, Alprazolam and Placebo in Outpatients with Panic Disorder. Protocol # C201
 Sponsor: Sandoz Pharmaceuticals Corp.
- 1989 Collaborative Fixed-Dose Study of the Efficacy and Safety of Deracyn-SR Tablets in Panic Disorder with Agoraphobia. Protocol # M/2300/0046
 Sponsor: The Upjohn Company
- 1990 Tomoxetine/Desipramine/Placebo Trial in MDD (Major Depressive Disorder). Protocol # B4Z-MC-HFAY
 Sponsor: Eli Lilly and Company
- 1990 Tramadol Hydrochloride: Long-Term Safety in Patients with Chronic Nonmalignant Pain. Protocol # TKB
 Sponsor: R.W. Johnson Phar. Research Inst.
- 1990 Etoperidone: Efficacy and Safety in Outpatients with Major Depression. Protocol # ERA 0341 N
 Sponsor: R.W. Johnson Pharmaceutical Research Institute
- 1990 Double-Blind Comparative Study of the Efficacy and Safety of Misoprostol and Ranitidine in the Prevention of NSAID-Induced Gastric Ulcers and Upper GI Symptoms. Protocol # S81-88-02-006
 Sponsor: G.D. Searle and Company
- 1990 Double-Blind Placebo Controlled Study of the Efficacy and Safety of Misoprostol in the Healing of NSAID-Induced Gastric Ulcers. Protocol # S81-89-02-028
 Sponsor: G.D. Searle and Company
- 1990 Double-Blind Parallel Study of Tolectin Tolmetin Sodium 1000 mg. Daily versus 1800 mg. Daily in the Treatment of Osteoarthritis. Protocol # TECO
 Sponsor: R.W. Johnson Pharmaceutical Research Institute
- 1990 Double-Blind Parallel Study of Tolectin Tolmetin Sodium 1000 mg. Daily versus 1800 mg. Daily in the Treatment of Rheumatoid Arthritis. Protocol # TERU
 Sponsor: R.W. Johnson Pharmaceutical Research Institute

- 1990 A Triple-Blind, Placebo-Controlled Evaluation of Remoxipride in Prevention of Relapse in Schizophrenia. Protocol # MK-843-003-00
Sponsor: Merck Sharp & Dohme Research Laboratories
- 1991 Double-Blind Parallel Comparison of Sertraline, Imipramine and Placebo in Inpatients with Major Depression or Bipolar Disorder, Depressed. Protocol # 86-CE21-0239
Sponsor: Pfizer Pharmaceuticals, Inc.
- 1991 Fixed Dose, Double-Blind Study Comparing the Efficacy and Safety of Xanax SR Tablets vs Placebo in the Treatment of Panic Disorder Using Once Daily Dosing. Protocol # M/2300/0003
Sponsor: The Upjohn Company/IBRD
- 1991 Double-Blind, Placebo Controlled, Comparative Study of the Efficacy and Safety of Three Dosage Regimens of Misoprostol in the Prevention of NSAID-Induced Gastric Ulcers. Protocol # S81-89-02-053
Sponsor: G.D. Searle and Company
- 1991 Flexible-Dose, Double-Blind, Study Comparing Efficacy and Safety of Deracyn SR Tablets vs Xanax CT in the Treatment of Geriatric Outpatients with Clinical Anxiety. Protocol # M/2300/0097
Sponsor: The Upjohn Company
- 1991 A Double-Blind Evaluation of Ketoprofen and Ibuprofen for Over-The-Counter Use. Protocol # 90-3
Sponsor: Oxford Research International
- 1991 A Prospective Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Groups Comparison of the Efficacy and Safety of Abecarnil (7.5 -17.5 mg) and Alprazolam (1.5 - 3.5 mg) in Outpatients with Generalized Anxiety Disorder. Protocol # B351
Sponsor: Sandoz Pharmaceutical Corp.
- 1992 Zatosetron Maleate in Patients with Generalized Anxiety Disorder - F2V-MC-HKAA, IND 37715.
Protocol # F2V-MC-HKAA
Sponsor: Eli Lilly and Co.
- 1992 A Prospective, Randomized, Double-Blind, Multicenter, Parallel-Groups Comparison of the Efficacy and Safety of Abecarnil (7.5 - 17.5 mg) and Placebo in Outpatients with Generalized Anxiety Disorders. Protocol # B356
Sponsor: Sandoz Pharmaceutical Corp.
- 1992 A Prospective, Randomized, Double-Blind, Placebo Controlled, Multicenter, Parallel-Groups Comparison of the Safety and Efficacy of Abecarnil (3.0 - 9.0 mg) and Lorazepam (1.5 - 4.5 mg) in Elderly Outpatients with Anxiety Symptoms. Protocol #B371
Sponsor: Sandoz Pharmaceutical Corp.
- 1992 A Phase II, Exploratory Study to Evaluate the Efficacy and Safety of CP-93,393 in Outpatients with Generalized Anxiety Disorder During a Nine- to Ten-Week Treatment Period. Protocol # 129-101-506
Sponsor: Pfizer, Inc.
- 1992 A Multicenter, Double-Blind, Placebo-Controlled Comparison of Low and High Dosage Regimens of ICI 204,636 in the Treatment of Hospitalized Patients with Acute Exacerbation of Subchronic or Chronic Schizophrenia. Protocol # 5077IL/0001
Sponsor: ICI Pharmaceuticals Group
- 1992 Dose-Response Study with Fixed Doses of New Alprostadil Sterile Powder (PGE₁) Formulation in Patients with Erectile Dysfunction. Protocol # M/5650/0069
Sponsor: The Upjohn Company

- 1992 Amesergide (LY237733) vs Placebo in the Treatment of Patients with Psychogenic Impotence.
Protocol # F2P-MC-LCAE
Sponsor: Eli Lilly and Company
- 1992 L-365,260 vs Placebo in Panic Disorder. Protocol # L-365,260
Sponsor: Merck, Sharp & Dohme Research Laboratories
- 1992 Long-Term Safety with Alprostadil Sterile Powder (PGE₁) (Alprostadil S. Po.) in Patients with Erectile Dysfunction. Protocol # M/5650/0070
Sponsor: The Upjohn Company
- 1992 A Phase II, 8 - Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Oral CP-93,393-102 in Outpatient's with Generalized Anxiety Disorder.
Protocol #129-102-506
Sponsor: Pfizer, Inc.
- 1993 A Phase II, 6 - Week, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Oral CP-93,393-103 in Outpatient's with Major Depressive Disorder. Protocol # 129-103-506
Sponsor: Pfizer, Inc.
- 1993 A Multicenter, Double-Blind, Randomized, Controlled, Multiple Fixed-Dose and Dose Regimen Comparison of Seroquel (ICI 204,636) and Haloperidol in the Prevention of Psychotic Relapse in Outpatients with Chronic or Subchronic Schizophrenia. Protocol# 5077IL/0015:0017
Sponsor: Zeneca Pharmaceuticals Group
- 1993 A Multicenter Double-Blind, Placebo-Controlled, Randomized, Multiple Fixed Dose Comparison of Seroquel (ICI 204,636) and Haloperidol in the Treatment of Hospitalized Subjects with Acute Exacerbation of Chronic or Subchronic Schizophrenia. Protocol # 5077IL/0013:0025
Sponsor: Zeneca Pharmaceuticals Group
- 1993 A Double-Blind Placebo-Controlled Dose Escalation Study of the Safety and Efficacy of Oral Ondansetron in the Treatment of Patients with Panic Disorder. Protocol #S3A-322
Sponsor: Glaxo Research Institute
- 1993 A Double Blind Trial Comparing Nefazodone to Fluoxetine in Patients with Activation Side Effects Previously Demonstrated During Treatment with Fluoxetine for Major Depressive Disorder.
Protocol #CN-103
Sponsor: Bristol-Myers Squibb Company
- 1993 Fixed-Dose, Double-Blind Pilot Study in Panic Disorder Comparing the Effects of Routine Clinical Taper and Taper by Progressive Placebo Substitution in Panic Patients Responding to Treatment with Deracyn Tablets.
Protocol # M/2300/0101
Sponsor: The Upjohn Company
- 1993 Multi-Center, 36 Week, Double-Blind, Parallel Group Safety, Tolerance and Efficacy Comparison of Placebo and Mentane (225 mg/d, 300 mg/d and 375 mg/d) in Outpatients with Alzheimer's Disease.
Protocol #HP029-303
Sponsor: Hoechst-Roussel Pharmaceuticals, Inc./Kendle Research Associates)
- 1993 Safety and Efficacy of Depakote in the Prevention of Mania in Patients with Bipolar Disorder.
Protocol # M92/822
Sponsor: Abbott Laboratories

- 1994 A Phase II, Six Week, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Oral CP-93,393-1 in Outpatients with Generalized Anxiety Disorder. Protocol #: 129-105-506
Sponsor: Pfizer Inc.
- 1994 Klonopin Dose Titration Study. Protocol # NZ14275B
Sponsor: Hoffmann LaRoche, Inc.
- 1994 An Exploratory Study of the Effect of Intracavernosal Alprostadil in Patients Suffering From Premature Ejaculation. Protocol # M/5655/0001
Sponsor: The Upjohn Company
- 1994 Phase III, Six Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Two Fixed Doses of Oral CP-88,059-1 (40 mg, BID and 80 mg, BID) in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder. Protocol # 128-108
Sponsor: Pfizer, Inc.
- 1994 A 52-Week, Open Extension Study Evaluating the Safety and Outcome of 40-80 mg, BID of Oral Ziprasidone (CP-88,059-1) Daily in the Treatment of Subjects who have Participated in Previous Ziprasidone (CP-88,059-1) Clinical Trials. Protocol # 128-116B
Sponsor: Pfizer, Inc.
- 1995 A Phase II, Eight Week, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Oral CP-93,393-1 in Outpatients with Major Depressive Disorder. Protocol # 129-106-506
Sponsor: Pfizer, Inc.
- 1995 A Randomized Double-Blind Placebo Controlled Dose-Ranging Study of the Efficacy and Tolerability of SB 202026 in Patients Suffering From Dementia of the Alzheimer's Type. Protocol # 202026/005
Sponsor: SmithKline Beecham Pharmaceuticals
- 1995 Fluoxetine/Placebo in Panic Disorder. Protocol #B1Y-MC-HCHG
Sponsor: Eli Lilly and Company
- 1995 An Open Label Administration of SB 202026 in Patients Suffering from Dementia of the Alzheimer's Type. Protocol 202026/007
Sponsor: SmithKline Beecham Pharmaceuticals
- 1995 Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Finding Study of Venlafaxine-Extended Release Capsules in Outpatients with Generalized Anxiety Disorder. Protocol 600-B-210-US
Sponsor: Wyeth-Ayerst Research
- 1996 A Ten Week, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Oral CP-93,393-1 in Outpatients with Major Depressive Disorder. Protocol 129-107
Sponsor: Pfizer, Inc./Quintiles
- 1996 A Ten Week, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Oral CP-93,393-1 in Outpatients with Generalized Anxiety Disorder. Protocol 129-108
Sponsor: Pfizer, Inc./Quintiles
- 1996 Six-Month, Double-Blind, Placebo-Controlled, Parallel Group Comparison of Venlafaxine Extended Release Capsules and Placebo in Outpatients with Generalized Anxiety Disorder. Protocol 0600B2-218-US
Sponsor: Wyeth-Ayerst Research

- 1996 A Placebo-Controlled, Double-Blind, Flexible Dose Study of Sertraline in the Treatment of Post-Traumatic Stress Disorder. Protocol 96CE21-0682
Sponsor: Pfizer, Inc.
- 1996 Double-Blind, Placebo-Controlled Study of Venlafaxine-ER and Venlafaxine-OROS in Outpatients with Major Depression. Protocol 0600C1-217-US
Sponsor: Wyeth-Ayerst Research
- 1996 Fluoxetine Plus Pindolol Versus Fluoxetine Plus Placebo in the Treatment of Major Depression.
Protocol B1Y-MC-HZAA
Sponsor: Eli Lilly
- 1996 A 24-Week Open Label Extension Study of Sertraline in Outpatients with Post-Traumatic Stress Disorder
Protocol 95CE21-0672
Sponsor: Pfizer, Inc.
- 1996 A Double-Blind Comparison of Fixed Dose Sertraline and Placebo in the Treatment of Premenstrual Syndrome
Protocol 96CE21-0680
Sponsor: Pfizer, Inc.
- 1996 A Double-Blind, Placebo Controlled, Flexible Dosing Trial to Evaluate the Efficacy of Modified Release Paroxetine in the Treatment of Panic Disorder Protocol 29060/495
Sponsor: SmithKline Beecham
- 1996 A Double-Blind Continuation Study Comparing Sertraline and Placebo in Outpatients with Post-Traumatic Stress Disorder Protocol 96CE21-0703
Sponsor: Pfizer, Inc.
- 1997 A Double-Blind Trial of Three Fixed Doses of Nefazodone and Placebo in the Treatment of Patients with Panic Disorder. Protocol CN104-149
Sponsor: Bristol-Myers Squibb
- 1997 A Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of SR46349B in Outpatients with Major Depression. Protocol DRI2623
Sponsor: Sanofi
- 1997 A Randomized, Double-Blind, Placebo Substitution Trial of the Efficacy of Nefazodone in the Long Term Continuation Treatment of Patients with Panic Disorder. Protocol CN104-150
Sponsor: Bristol-Myers Squibb
- 1997 A Multicenter, Double-Blind, Placebo-Controlled, Parallel Group Study of the Safety, Tolerability and Efficacy of Three Fixed Doses of Fluvoxamine Versus Placebo in Outpatients with Major Depressive Disorder. Protocol S1143102
Sponsor: Solvay Pharmaceuticals, Inc.
- 1997 A Double-Blind, Multicenter, Dose-Finding Acute and Extension Study of MK-0869 (L-754,030) vs. Fluoxetine and Placebo in the Treatment of Outpatients with Major Depressive Disorder.
Protocol 020
Sponsor: Merck & Co., Inc.
- 1998 An International, Multicenter Trial of Two Dose Ranges of Nefazodone and Placebo in the Treatment of Outpatients with Posttraumatic Stress Disorder. Protocol CN104-159
Sponsor: Bristol-Myers Squibb

- 1998 A Six-Week, Double-Blind, Placebo- and Fluoxetine-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Oral CP-122,721 in Outpatients with Major Depressive Disorder. Protocol 165-112-5048
Sponsor: Pfizer, Inc.
- 1998 Almotriptan: A Long-Term Open Label Safety Study of Almotriptan 12.5 mg Orally in Migraine Patients
Protocol M/3275/0011
Sponsor: Pharmacia & Upjohn
- 1998 A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Fixed-Dose, 7-Week Evaluation of the Efficacy and Safety of Lamotrigine in Treatment of a Major Depressive Episode in Unipolar Depressed Patients. Protocol SCA20025
Sponsor: Glaxo Wellcome
- 1999 A Study of Low-Dose Flesinoxan in Patients with Generalized Anxiety Disorder (GAD; DSM-IV); A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess Efficacy and Safety.
Protocol H.128.5055
Sponsor: Solvay Pharmaceuticals
- 1999 Oral Almotriptan vs Oral Sumatriptan in a Double-Blind, Randomized, Parallel Group Study of Cost-Effectiveness and Quality of Life in Migraine. Protocol M/3275/0008
Sponsor: Pharmacia & Upjohn
- 1999 Duloxetine Versus Placebo in the Treatment of Major Depression. Protocol F1J-MC-HMAQ
Sponsor: Eli Lilly and Company
- 1999 Flexible Dose Comparison of the Safety and Efficacy of LU 26-054, Citalopram, and Placebo in the Treatment of Major Depressive Disorder. Protocol SCT-MD-02
Sponsor: Forest Laboratories, Inc.
- 1999 Flexible Dose Comparison of the Safety and Efficacy of LU 26-054, Citalopram, and Placebo in the Treatment of Panic Disorder. Protocol SCT-MD-04
Sponsor: Forest Laboratories, Inc.
- 1999 A Twelve-Week, Randomized, Double-Blind, Placebo Controlled, Flexible Dose Study of Fluvoxamine CR in the Treatment of Generalized Social Anxiety Disorder. Protocol S1143107
Sponsor: Solvay Pharmaceuticals, Inc.
- 1999 Placebo-Controlled Evaluation of the Safety and Efficacy of LU 26-054 in the Prevention of Depression Relapse. Protocol SCT-MD-03
Sponsor: Forest Laboratories
- 1999 A Placebo-Controlled Study of Pregabalin and Alprazolam in Patients with Generalized Anxiety Disorder
Protocol 1008-083
Sponsor: Parke-Davis
- 1999 A Double-Blind, Placebo-Controlled Study of a Flexible Dose of Venlafaxine ER in Adult Outpatients with Generalized Social Anxiety Disorder. Protocol 0600B4-387-US
Sponsor: Wyeth-Ayerst Research
- 2000 A Six-Week, Double-Blind, Placebo-Controlled Multicenter Study to Evaluate the Safety and Efficacy of 3 Doses of CP-448,187 (0.5, 3 and 10 mg) and Fluoxetine in Subjects with Major Depressive Disorder
Protocol A2721002
Sponsor: Pfizer, Inc.

- 2000 A 10-Week, Randomized, Double-Blind, Placebo-Controlled Study of Paroxetine and Pregabalin in Patients with Social Phobia. Protocol 1008-153-208
Sponsor: Parke-Davis
- 2000 Evaluation of the Safety and Efficacy of LU 26-054 in the Prevention of Depression Recurrence. Protocol SCT-MD-11
Sponsor: Forest Laboratories
- 2000 A Phase IIB, Six-Week, Double-Blind, Placebo- and Paroxetine-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Oral CP-122,721 in Outpatients with Major Depressive Disorder. Protocol A1651002
Sponsor: Pfizer, Inc.
- 2000 A Seven-Week, Double-Blind, Extension of Protocol A1651002: A Phase IIB, Six-Week, Double-Blind, Placebo- and Paroxetine-Controlled Multicenter Study to Evaluate the Safety and Efficacy of Oral CP-122,721 in Outpatients with Major Depressive Disorder. Protocol A1651007
Sponsor: Pfizer, Inc.
- 2000 Fixed Dose Continuation Study of Escitalopram in the Treatment of Depressed Nonresponders
Protocol SCT-MD-08
Sponsor: Forest Laboratories
- 2001 A Double-Blind, Multicenter, Placebo and Active Controlled Acute and Extension Study of 2 Doses of MK-0869 in the Treatment of Patients with Major Depression. Protocol 061
Sponsor: Merck Research Laboratories
- 2002 A Double-Blind, Placebo-Controlled Multicenter Study of the Long-Term Efficacy of MK-0869 in the Maintenance of Antidepressant Effect in Geriatric Outpatients with Major Depressive Disorder. Protocol 068
Sponsor: Merck Research Laboratories
- 2002 Ro 67-5930 in Major Depressive Disorder (MDD) A Placebo- and Paroxetine-Controlled Study of Efficacy and Safety Protocol #BN16430D
Sponsor: Hoffman-La Roche, Inc.
- 2003 A four-week double-blind, placebo and active controlled, dose-ranging study of SL 65.1498-00, 3 doses (5, 15, 50 mg per day) and lorazepam (3 mg/day) in out-patients with Generalized Anxiety Disorder (GAD). Protocol DRI4390
Sponsor: Sanofi-Synthelabo Research
- 2003 A multicenter, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of three fixed doses (50 mg, 100 mg, or 200 mg) of DVS-233 SR in adult outpatients with Major Depressive Disorder. Protocol 3151A1-306-US
Sponsor: Wyeth Pharmaceuticals, Inc.
- 2003 A 10-month open-label evaluation of the long-term safety of DVS-233 SR on outpatients with Major Depressive Disorder. Protocol 3151A1-303-WW
Sponsor: Wyeth Pharmaceuticals, Inc.
- 2003 A double-blind, multicenter, randomized, placebo-controlled efficacy and safety study of ORG 33062 ER in subjects with Major Depressive Disorder. Protocol FKGBE008
Sponsor: Faber-Kramer Pharmaceuticals, Inc.
- 2004 A Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Examine the Efficacy of Rizatriptan 10 mg Tablet Administered Early During a Migraine Attack While the Pain is Mild. Protocol 065-00 Sponsor: Merck & Co., Inc.

- 2004 A 10-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Flexible-Dosage Study to Evaluate the Efficacy and Safety of GABITRIL® (up to 16mg/day) in the Treatment of Adults with Generalized Anxiety Disorder. Protocol C6671/3031/AX/US
Sponsor: Cephalon, Inc.
- 2004 A 6-Month Open-Label Evaluation of the Long-Term Safety of DVS-233SR in Elderly Outpatients. Protocol 3151A1-307-US
Sponsor: Wyeth Research
- 2004 A Randomized, Double-Blind, Placebo and Active Comparator Controlled, Parallel-Group Safety and Efficacy Study of OROS® Alprazolam in Adults with Generalized Anxiety Disorder (GAD) Protocol 04-001-01
Sponsor: Jazz Pharmaceuticals
- 2005 A Long-Term, Open-Label, Safety and Efficacy Study of OROS® Alprazolam in Adults with Generalized Anxiety Disorder (GAD). Protocol 04-003-00
Sponsor: Jazz Pharmaceuticals
- 2005 A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety and Efficacy of GABITRIL® Treatment (up to 16 mg/day) in Adults with Generalized Anxiety Disorder. Protocol C6671/3033/AX/US
Sponsor: Cephalon, Inc.
- 2005 A 6-Month Open-Label Evaluation of the Long-Term Safety of DVS-233SR In Elderly Outpatients. Protocol No. 3151A1-307-US
Sponsor: Wyeth Pharmaceuticals
- 2005 A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Bifeprunox in the Treatment of Depression in Outpatients with Bipolar Disorder. Protocol 3168A2-304-US
Sponsor: Wyeth Pharmaceuticals
- 2005 An Extension Study to Evaluate the Long-Term Safety and Tolerability of Bifeprunox in the Treatment of Outpatients with Bipolar Disorder. Protocol 3168A2-307 Sponsor: Wyeth Pharmaceuticals
- 2005 An Eight-Week, Double-Blind, Placebo-Controlled, Multicenter Study with Escitalopram (10 mg qd) as Positive Control, Evaluating the Efficacy, Safety, and Tolerability of a Fixed Dose of SR58611A (350 mg q12) in Outpatients with Major Depressive Disorder (MDD). Protocol EFC 5041
Sponsor: Sanofi-Aventis, Inc.
- 2006 A multicenter, randomized, 30- to 52-week, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of saredutant 100 mg once daily in the prevention of relapse or recurrence of depressive symptoms in outpatients with major depressive disorder who maintained clinical stability after an initial response to open-label treatment with saredutant 100 mg once daily. Protocol EFC 5576
Sponsor: Sanofi-Aventis, Inc.
- 2006 A Multi-centre, Double-blind, Randomized-withdrawal, Parallel-group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (SEROQUEL SR™) as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-label Stabilization Period. Protocol D1448C00005
Sponsor: Astra Zeneca Pharmaceuticals
- 2006 A Phase 2, Double-Blind, Placebo-Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects with Social Anxiety Disorder Protocol AV608-105
Sponsor: Avera Pharmaceuticals

- 2006 A Phase III Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients with Postherpetic Neuralgia
Protocol 81-0045 Sponsor: Depomed, Inc.
- 2006 Patient Outcomes With Education, Drug Therapy, and Support (POETS) – A Multicenter, Open Label, Randomized, Study to Evaluate Depressed Patients Treated with Venlafaxine Extended-Release Vs. Venlafaxine Extended-Release Plus Dialogues Time to Talk Program in a Primary Care Setting
Protocol 0600B1-416-US Sponsor: Wyeth Pharmaceuticals
- 2007 A Multi-centre, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR™) as Mono-Therapy in the Treatment of Elderly Patients with Major Depressive Disorder (SAPPHIRE STUDY)
Protocol D1448C00014 Sponsor: Astra Zeneca
- 2007 A Multi-Centre, Double-Blind, Randomized, Parallel-Group, Placebo-Controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR™) as Mono-therapy in the Treatment of Elderly Patients with Generalized Anxiety Disorder (CHROMIUM STUDY)
Protocol D1448C00015 Sponsor: Astra Zeneca
- 2007 A Randomized, Double-Blind, Two-Arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder
Protocol 04ACL3-001 Sponsor: Labopharm, Inc.
- 2007 An eight-week, double-blind, placebo-controlled study to evaluate the efficacy, safety and tolerability of saredutant 100 mg once daily in combination with escitalopram 10 mg once daily in patients with major depressive disorder
Protocol EFC 10290 Sponsor: Sanofi-Aventis
- 2007 A multi-center, double-blind, parallel group, fixed dose, 4-arm, placebo and paroxetine controlled 8-week efficacy study of 2 oral doses of SR58611A (175 mg or 350 mg, b.i.d.) in adult population with Major Depressive Disorder
Protocol C10953/2032/DP/US Sponsor: Cephalon, Inc.
- 2007 Efficacy and Safety of 2mg/day of MI00907 on Sleep Maintenance Insomnia with a sub-study of the effect of MI 00907 on stable Type II Diabetes Mellitus: a 12-week, multi-center, randomized, double-blind, placebo-controlled study.
Protocol LTE6672 Sponsor: Sanofi-Aventis